cogane Pages on BioPortfolio:

BioPortfolio - sapogenin cogane
sapogenin cogane - BioPortfolio. ... sapogenin cogane Pages on BioPortfolio:. Results from other life science and pharmaceutical sites: ...
http://www.bioportfolio.com/search/sapogenin_cogane.html...

BioPortfolio - Phase II Myogane
BioPortfolio - Phase II Myogane Cogane™ is in clinical development as a treatment ... Our pharmaceutical products Cogane™ and Myogane™ continue to make
. ...
http://www.bioportfolio.com/search/Phase_II_Myogane.html...

BioPortfolio - Phytopharm Plc
Full confidential disclosure of the substantial data sets for both Cogane™ and Myogane™, our lead products for Alzheimer’s and motor neurone disease, ...
http://www.bioportfolio.com/biocorporate/28354-Phytopharm_Pl...

BioPortfolio - Phytopharm plc
and two compounds in development by Phytopharm plc, PYM-50028 (Cogane) and . ... $1.16 million funding for Cogane™ - Phytopharm plc GODMANCHESTER, . ...
http://www.bioportfolio.com/search/Phytopharm_plc.html...

BioPortfolio - Phytopharm Plc - Profile
of the substantial data sets for both Cogane™ and Myogane™, our lead products for Alzheimer’s and motor. neurone disease, are now in progress with ...
http://www.bioportfolio.com/biocorporate/28353-Phytopharm+Pl...

Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 ...
7.3.4.5 Phytopharm Cogane -an orally active neuroprotective compound 7.3.4.6 Nicotine Replacement Therapy as a Potential Treatment for AD ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_86.html...

Pipeline and Commercial Insight: Alzheimer's Disease - Scenario ...
Cogane 170 Drug overview 170 Clinical trial data 170 Other drugs targeting disease modifying modes of action 172 Ketasyn 172 AL-108 172 HF0220 173 ...
http://www.bioportfolio.com/cgi-bin/acatalog/info_320.html...

Results from other life science and pharmaceutical sites:

Cogane™ - Phytopharm plc
Importantly, Cogane™ also reverses the decrease of neuronal growth factors and reverses neuronal ... administered orally to preclinical models Cogane™ ...
http://www.phytopharm.com/portfolio/?id=2134...

The Michael J. Fox Foundation for Parkinson's Research - Research ...
The objective of this project is to assess the effects of oral administration of Cogane™ in reversing the changes in the area of the brain involved in ...
http://www.michaeljfox.org/research_MJFFfundingPortfolio_sea...

Cogane™ - Phytopharm plc
Importantly, Cogane™ also reverses the decrease of neuronal growth ... Cogane™ restores the learning and memory ability in preclinical models ...
http://www.phytopharm.com/portfolio/?id=2234...

Interim Management Statement for 3 months ended 30 June 2008 ...
30 Jun 2008 ... Cogane™. On target for Phase IIa clinical trial in Parkinson’s disease ... Our pharmaceutical products Cogane™ and Myogane™ continue to make ...
http://www.phytopharm.com/news/newsreleases/?id=8488...

{1} Announces Results Of Interim Data Review For Phase II Proof Of ...
Dr. Richard Dixey, Chief Executive of Phytopharm, said: "We are encouraged by the emerging safety profile of Cogane(TM) and look forward to completing the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1874452...

News Releases - Phytopharm plc
$1.16 million funding for Cogane™. 21 January 2008. Phytopharm plc (LSE: PYM) (“ Phytopharm” or the “Company”) announces today that it has been awarded ...
http://www.phytopharm.com/news/newsreleases/...

Natural Products in Drug Discovery and Development Alan Harvey
Phytopharm plc, PYM-50028 (Cogane) and PYM-50018. (Myogane), for the treatment of neurodegenerative disease. Introduction ...
http://www.biomedcentral.com/content/pdf/cd-619165.pdf...

Portfolio - Phytopharm plc
Cogane™. Neurotrophic factor inducer. Motor Neurone Disease(ALS; Lou Gehrig's disease) and other orphan neurodegenerative diseases ...
http://www.phytopharm.com/portfolio/...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.